Exchange: NASDAQ·Updated 06:13 AM EDT
CLRB logo

CLRB Cellectar Biosciences Inc

$2.40
$0.02
(0.84%)
Pre-Market
Prev Close $2.38
EarningsNov 12
Mkt Cap$22.5M
Vol59.00

About CLRB

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124, which could detect tumors and metastases in a broad range of cancers, and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on June 24, 1996 and is headquartered in Florham Park, NJ.
63

Bullish Sentiment

How do you feel about CLRB?

EvenBetter99
$CLRB revolutionary Phospholipid Drug Conjugate (PDC) technology provides high-precision oncology delivery by directly targeting cancer cell membranes while sparing healthy tissue. Fir example WaM efficency over 83.6% ORR, 61.8 % MRR, 100 % CBR💪💪💪 This highly versatile platform forms the basis for their crucial Phase 1b catalyst trial evaluating the Auger-emitting radioconjugate CLR 125. It brings remarkable new hope as a highly effective, tailored treatment for patients fighting refractory triple-negative breast cancer (TNBC) and validates the plattform immensly. 🍀🍀🍀🍀🚀🚀🚀
3
Sloan88
$CLRB if you see a $2.88 pop in the morning it’s most likely me makes me feel good for a few hours🤷🏻‍♂️🤷🏻‍♂️🤷🏻‍♂️plus I’m up over 100k last 60 days and now 10k share club member🚀🚀🚀🚀🚀
3
M31V1
$CLRB If they receive an offer in the $150M ballpark, I would seriously consider it. There could be substantially more upside if the assets execute well but that outcome is far from certain and comes with significant clinical, regulatory, financing, and execution risk.
1

Advertisement|Remove ads.